Treatment for Guillain-Barré Syndrome
Intravenous immunoglobulin (IVIg) at 0.4 g/kg body weight daily for 5 days is the first-line treatment for adults with GBS who cannot walk independently. 1
First-Line Treatment Options
Both IVIg and plasma exchange are equally effective for GBS, but IVIg is preferred as first-line therapy because it is easier to administer, more widely available, and has fewer adverse effects requiring treatment discontinuation 1.
Dosing Regimens
For IVIg:
- 0.4 g/kg body weight daily for 5 consecutive days (total dose: 2 g/kg) 1
- This is the standard regimen for adults
For Plasma Exchange (alternative):
- Five sessions of 200-250 ml plasma/kg body weight 1
- Typically performed over 7-14 days
- Requires specialized equipment and trained personnel
- More likely to cause complications requiring discontinuation 1
When to Treat
Initiate treatment when patients meet these criteria:
- GBS disability score ≥3 (unable to walk independently without assistance) 2
- Within 2 weeks of symptom onset for IVIg 2
- Within 4 weeks of symptom onset for plasma exchange 2
The evidence base for these treatments comes primarily from trials of patients with AIDP subtype and moderate-to-severe disease, so these parameters guide treatment decisions 2.
What Does NOT Work
Avoid these interventions:
- Corticosteroids alone are ineffective and oral corticosteroids may worsen outcomes 1
- Combination therapy (plasma exchange followed by IVIg) provides no additional benefit over either treatment alone 1
- Adding intravenous methylprednisolone to IVIg has insufficient evidence for routine use 1
Special Populations
Pregnant women:
- Neither IVIg nor plasma exchange is contraindicated
- IVIg is preferred due to simpler administration and monitoring requirements 1
Children:
- Use the same adult dosing: 0.4 g/kg daily for 5 days
- Do NOT use the 2-day regimen (2 g/kg over 2 days) as it causes more treatment-related fluctuations 1
- IVIg is strongly preferred over plasma exchange in children due to greater discomfort and complication rates with plasma exchange 1
Miller Fisher Syndrome (MFS):
- Treatment generally not recommended for pure MFS as most recover completely within 6 months without intervention
- Monitor closely as some patients develop limb weakness, bulbar palsy, or respiratory failure requiring treatment 1
Bickerstaff Brainstem Encephalitis (BBE):
- Treat with IVIg or plasma exchange given the severe disease course, despite limited evidence 1
Critical Monitoring Requirements
Respiratory function must be monitored closely as up to 22% of patients require mechanical ventilation within the first week 1. Admit to ICU if:
- Vital capacity <15-20 ml/kg or <1 liter
- Unable to count to 15 in one breath
- Breathlessness at rest or during talking
- Use of accessory respiratory muscles
- Rapid progression of weakness
- Severe autonomic dysfunction or swallowing impairment 1
Common Pitfalls
Do not repeat IVIg or add plasma exchange routinely if patients fail to respond initially—approximately 10% of patients experience treatment-related fluctuations, but combination therapy is not more effective 1. If true treatment failure occurs (not just fluctuation), consider plasma exchange if IVIg was used first, or vice versa.
Do not delay treatment waiting for electrophysiological confirmation—diagnosis is clinical, and treatment should begin once the patient cannot walk independently 1.
Do not use corticosteroids unless you suspect acute-onset CIDP (A-CIDP) due to prolonged progressive course beyond 8 weeks 3.
Resource-Limited Settings
In settings where standard treatments are unaffordable, small-volume plasma exchange (SVPE) has shown promise as a low-cost alternative (~$500 vs $4,500-16,000), but cannot be recommended for routine use until larger efficacy trials are completed 2.